CTLA4 and neoplasm: Targeting Tregs using anti‐CTLA4 antibody combined with M1 oncolytic viruses induced tumor suppression and lymphocytotoxicity via decreasing Tregs and increasing the infiltration of CD45+ immune cells CD4+ or CD8+ T cells, releasing IFN‐γ, perforin, and granzyme.